Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 407

1.

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.

Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL.

Eur Heart J. 2018 Apr 13. doi: 10.1093/eurheartj/ehy162. [Epub ahead of print]

PMID:
29668889
2.

Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.

Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ, Mont L, Morillo CA, Smolnik R, Yin OQP, Kautzner J.

Clin Cardiol. 2018 Apr 17. doi: 10.1002/clc.22918. [Epub ahead of print]

3.

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.

Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L.

Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.

PMID:
29653640
4.

Digoxin and Mortality in Patients With Atrial Fibrillation.

Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L; ARISTOTLE Committees and Investigators.

J Am Coll Cardiol. 2018 Mar 13;71(10):1063-1074. doi: 10.1016/j.jacc.2017.12.060.

PMID:
29519345
5.

Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.

Hohnloser SH, Basic E, Hohmann C, Nabauer M.

Thromb Haemost. 2018 Mar;118(3):526-538. doi: 10.1160/TH17-10-0733. Epub 2018 Jan 22.

PMID:
29359278
6.

Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy.

Vamos M, Healey JS, Wang J, Connolly SJ, Mabo P, Van Erven L, Kautzner J, Glikson M, Neuzner J, O'Hara G, Vinolas X, Gadler F, Hohnloser SH.

Heart Rhythm. 2018 Mar;15(3):386-392. doi: 10.1016/j.hrthm.2017.11.020. Epub 2017 Nov 20.

PMID:
29157723
7.

Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations.

Erath JW, Hohnloser SH.

Herz. 2018 Feb;43(1):2-10. doi: 10.1007/s00059-017-4648-0.

PMID:
29147720
8.

Off-Label Use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients With Prosthetic Valves.

Chaturvedi S, Molina CA, Selim MH, Diener HC, Hohnloser SH.

Stroke. 2017 Nov;48(11):3183-3186. doi: 10.1161/STROKEAHA.117.017592. Epub 2017 Oct 13. No abstract available.

PMID:
29030474
9.

Usefulness of the WCD in patients with suspected tachymyopathy.

Erath JW, Vamos M, Benz AP, Hohnloser SH.

Clin Res Cardiol. 2018 Jan;107(1):70-75. doi: 10.1007/s00392-017-1159-1. Epub 2017 Oct 9.

PMID:
28993851
10.

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators.

N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.

PMID:
28844193
11.

Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.

Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, Mairesse GH, Mabo P, Camm AJ, Healey JS.

Am Heart J. 2017 Jul;189:137-145. doi: 10.1016/j.ahj.2017.04.008. Epub 2017 Apr 24.

PMID:
28625370
12.

Ventricular rate stabilization for treatment of recurrent VT.

Vamos M, Bogyi P, Duray GZ, Nyolczas N, Hohnloser SH.

Herzschrittmacherther Elektrophysiol. 2017 Jun;28(2):239-242. doi: 10.1007/s00399-017-0513-3. Epub 2017 May 31. Review.

PMID:
28567490
13.

Drugs to prevent sudden cardiac death.

Erath JW, Hohnloser SH.

Int J Cardiol. 2017 Jun 15;237:22-24. doi: 10.1016/j.ijcard.2017.03.066. Epub 2017 Mar 18. Review.

PMID:
28341373
14.

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.

Essebag V, Proietti R, Birnie DH, Wang J, Douketis J, Coutu B, Parkash R, Lip GYH, Hohnloser SH, Moriarty A, Oldgren J, Connolly SJ, Ezekowitz M, Healey JS.

Europace. 2017 Oct 1;19(10):1630-1636. doi: 10.1093/europace/euw409.

PMID:
28339794
15.

Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.

Van Gelder IC, Healey JS, Crijns HJGM, Wang J, Hohnloser SH, Gold MR, Capucci A, Lau CP, Morillo CA, Hobbelt AH, Rienstra M, Connolly SJ.

Eur Heart J. 2017 May 1;38(17):1339-1344. doi: 10.1093/eurheartj/ehx042.

PMID:
28329139
16.

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.

Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M; RE-CIRCUIT Investigators.

N Engl J Med. 2017 Apr 27;376(17):1627-1636. doi: 10.1056/NEJMoa1701005. Epub 2017 Mar 19.

17.

Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study.

Hohnloser SH, Basic E, Nabauer M.

Clin Res Cardiol. 2017 Aug;106(8):618-628. doi: 10.1007/s00392-017-1098-x. Epub 2017 Mar 14.

PMID:
28293797
18.

Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter-Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS (Substrate Modification Study).

Kuck KH, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, Zarse M, Hohnloser SH, Kautzner J, Willems S; SMS Investigators.

Circ Arrhythm Electrophysiol. 2017 Mar;10(3). pii: e004422. doi: 10.1161/CIRCEP.116.004422.

19.

Effects of Upgrade Versus De Novo Cardiac Resynchronization Therapy on Clinical Response and Long-Term Survival: Results from a Multicenter Study.

Vamos M, Erath JW, Bari Z, Vagany D, Linzbach SP, Burmistrava T, Israel CW, Duray GZ, Hohnloser SH.

Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004471. doi: 10.1161/CIRCEP.116.004471.

20.

Not All Types of Atrial Fibrillation Carry the Same Stroke Risk, but Most Benefit From Oral Anticoagulation.

Hohnloser SH, Vamos M.

Circ Arrhythm Electrophysiol. 2017 Jan;10(1). pii: e004847. doi: 10.1161/CIRCEP.116.004847. No abstract available.

Supplemental Content

Loading ...
Support Center